Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 27, 2026.

Direct cysteine sulfenylation drives activation of the Src kinase

David E. Heppner, Christopher M. Dustin, Chenyi Liao and 9 more (opens in a new tab)

Nature Communications · 2018 · CC BY

doi:10.1038/s41467-018-06790-1 (opens in a new tab)

Abstract

The Src kinase controls aspects of cell biology and its activity is regulated by intramolecular structural changes induced by protein interactions and tyrosine phosphorylation. Recent studies indicate that Src is additionally regulated by redox-dependent mechanisms, involving oxidative modification(s) of cysteines within the Src protein, although the nature and molecular-level impact of Src cysteine oxidation are unknown. Using a combination of biochemical and cell-based studies, we establish the critical importance of two Src cysteine residues, Cys-185 and Cys-277, as targets for H 2 O 2 -mediated sulfenylation (Cys-SOH) in redox-dependent kinase activation in response to NADPH oxidase-dependent signaling. Molecular dynamics and metadynamics simulations reveal the structural impact of sulfenylation of these cysteines, indicating that Cys-277-SOH enables solvent exposure of Tyr-416 to promote its (auto)phosphorylation, and that Cys-185-SOH destabilizes pTyr-527 binding to the SH2 domain. These redox-dependent Src activation mechanisms offer opportunities for development of Src-selective inhibitors in treatment of diseases where Src is aberrantly activated.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 27, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

The proto-oncogene protein tyrosine kinase Src is the prototypical member of the Src-family kinases (SFKs) that participate in cell signaling pathways by catalyzing phosphorylation of specific tyrosine residues in various target proteins. Commonly activated by initial activation of cell surface receptors, Src controls various cellular outcomes, including differentiation, adhesion, migration, and proliferation,. As the first characterized proto-oncogene, it is well appreciated that aberrant Src activation and expression is associated with malignant transformation and oncogenesis establishing Src as a chemotherapeutic target in the treatment of various cancers. Additionally, pharmacological inhibition of Src and other SFKs have been shown to be effective in several nonmalignant human diseases,. Therefore, elucidation of factors that regulate Src activation is critical to understanding its extensive roles in human disease and for development of effective treatments.

A nonreceptor tyrosine kinase, Src activity is regulated through protein structural changes triggered by intramolecular domain interactions through Src homology (SH) 2 and 3 domains and by (de)phosphorylation of key tyrosine residues, thereby coupling activation of Src with targeting of appropriate cellular substrates. In its autoinhibited form, Src is phosphorylated at Tyr-527 (pTyr) (chicken sequence numbers used throughout) within the C-terminal tail, which promotes its binding to the SH2 domain, maintaining the protein in a minimally active “clamped” confirmation. Upon dephosphorylation of pTyr-527, Src unfolds inducing several structural changes, which allows for binding to downstream targets. The structural hallmark of the maximally active Src kinase is the unfolded activation loop (A-loop) α-helix, which exposes Tyr-416 for phosphorylation and sustains maximal kinase activity. Molecular modeling studies describe a dynamic molecular model for Src kinase activation involving initial conversion of the autoinhibited kinase to an active-like state, in a two-step process with A-loop unfolding followed by αC-helix rotation,. These two states exist in equilibrium, favoring the autoinhibited conformation. Subsequent (auto)phosphorylation of Tyr-416 by intermolecular encounter with another active kinase then stabilizes the active form of Src,. In addition to Tyr-416, phosphorylation of additional tyrosines may also regulate SFK function.

In addition to regulation by tyrosine (de)phosphorylation, accumulating evidence indicates that Src activation occurs in association with increased cellular production of reactive oxygen species (ROS). ROS generated from NADPH oxidases (NOX), respiring mitochondria, or other sources are capable of modulating signaling pathways by reversible oxidation of conserved cysteine (Cys-SH) residues within target proteins,. Such reversible redox modifications have been implicated in regulation of tyrosine phosphorylation, which is largely attributed to inactivation of protein tyrosine phosphatases by reversible oxidation of their catalytic cysteines, thereby resulting in enhanced or extended tyrosine phosphorylation. However, tyrosine kinases themselves are also subject to direct redox regulation by oxidation of noncatalytic cysteines–. Indeed, tyrosine kinases such as the epidermal growth factor receptor (EGFR) and SFKs interact directly with NOX enzymes during their activation–, and recent studies by our group,– and others, indicate that NOX-mediated activation of Src and EGFR closely associates with cysteine oxidation within these kinases. The Src protein contains nine cysteine residues, most of which are conserved among SFKs and related kinases (Supplementary Fig. 1 and Supplementary Table 1), and studies with cysteine mutants have suggested the involvement of several of these cysteines in ROS-mediated Src activation–. However, the molecular mechanisms by which cysteine oxidation promotes Src kinase activity remain unclear, and studies with recombinant Src proteins confoundingly indicate that ROS or other thiol-reactive agents can also inactivate kinase activity,,.

Oxidation of cysteine by H2O2, the main mediator of NOX-mediated redox signaling, initially generates a sulfenic acid (Cys-SOH), but generates additional oxidative modifications in subsequent reactions. Recent studies indicate that redox-dependent activation of tyrosine kinases such as Src or EGFR closely associates with initial formation of Cys-SOH, the proximal product of cysteine oxidation by H2O2, and that other oxidative modifications such as S-glutathionylation do not enhance kinase activity,,,. The present studies were conducted to characterize the redox-sensitive cysteine residues within Src that are most susceptible to sulfenylation, and to identify the impact of this modification on tyrosine kinase activity. We identified Cys-185 and Cys-277 as the primary Cys residues oxidized to Cys-SOH by H2O2, and demonstrated that oxidation of both cysteines is critical for redox-dependent kinase activation. Molecular dynamics (MD) and metadynamics simulations indicate that modification of these cysteines to Cys-SOH induces local structural changes that directly impact the regulatory pTyr-527 and Tyr-416 residues, respectively.

Sulfenylation of Cys-185 and Cys-277 enhances Src activity

To identify the redox-active Src cysteine residues that are susceptible to sulfenylation by H2O2, we utilized various sulfenic acid-selective trapping reagents to assess H2O2-induced cysteine modifications in recombinant Src using liquid chromatography-tandem mass spectrometry (LC–MS/MS). First, recombinant Src (~20 µg) was treated with various concentrations of H2O2 (0.1–100 mM) in the presence of 5,5′-dimethyl-1,3-cyclohexanedione (dimedone) to trap Cys-SOH species, and then trypsin digested for MS analysis. These analyses typically yielded ~80% peptide coverage, comprising all nine cysteine residues. In the absence of H2O2, all cysteines were detected as iodoacetamide adducts, and no dimedone adducts were observed (except at Cys-498), suggesting they were reduced. In contrast, upon H2O2 treatment, Cys-S-dimedone modifications were observed at three cysteines (Cys-185, Cys-277, and Cys-498), indicating that they were sulfenylated by H2O2 and trapped as dimedone adducts (Supplementary Fig. 2; Supplementary Table 2 and Supplementary Data 1). Other cysteine modifications, such as sulfinic and sulfonic acids, were also identified on several cysteines, but were also observed in untreated Src (Supplementary Data 1), presumably due to autoxidation during purification and processing. Oxidation of Src by high doses of H2O2 (100 mM) revealed overoxidized Cys-185 and Cys-277 (to sulfonic acids; Supplementary Data 1), which further supports the notion that Cys-185 and Cys-277 are redox active. Importantly, while no Cys-S-dimedone adducts were observed on other cysteines, oxidation of Src with high amounts of H2O2 (>1 mM) induced DTT-reducible mass shifts upon analysis by Coomassie stained sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), indicative of intra- and/or intermolecular disulfide crosslinking, which were in some cases independent of Cys-185 or Cys-277 (Supplementary Fig 3).

One limitation of dimedone is its relatively slow reaction rate with sulfenic acids, suggesting that some intermediate Cys-SOH may have gone undetected. We, therefore, performed similar analysis with an alternative sulfenic acid-reactive probe, bicyclo[6.1.0]nonyne (BCN), which is known to react with Cys-SOH with a 100-fold faster rate to form –S(O)-BCN adducts,. Global LC–MS/MS analysis did not reveal formation of –S(O)-BCN adducts in unreacted Src, but adducts were detected on three cysteines during reaction of Src with H2O2, namely Cys-185, Cys-245, Cys-277, and not observed on any other cysteines (Supplementary Fig. 4, Supplementary Table 2, and Supplementary Data 2). Importantly, BCN can also react with Cys-SH,, but this caveat is easily addressed since reaction with Cys-SOH yields a peptide [Cys-S(O)-BCN] + 16 Da heavier than reaction products with a thiol (Cys-S-BCN). Indeed, our MS analysis did not reveal detectable peptides containing Cys-S-BCN in unreacted or H2O2-treated Src. Finally, we also assessed cysteine sulfenylation in the presence of 4-chloro-7-nitrobenzofurazan (NBD-Cl), and observed that H2O2-treated Src contained detectable Cys-S(O)-NBD adducts at Cys-277 and Cys-498, consistent with Cys-SOH formation at these residues (Supplementary Table 2 and Supplementary Data 3).

To more rigorously identify and quantify the most susceptible redox-sensitive Src Cys residues, we performed quantitative MS analysis of dimedone trapping using labeling with light dimedone (dim-d0) and heavy dimedone (dim-d6) of nonoxidized and H2O2-treated Src, respectively. Targeted mass spectrometry with parallel reaction monitoring (PRM) was performed to monitor all cysteine-containing peptides with dimedone/dimedone-d6 modifications. The targeted analysis not only further confirmed the dimedone labeled peptides identified from the exploratory mass spectrometry experiments with higher S/N and sequence coverage, but also identified other low-abundant dimedone containing peptides that were not identified in the previous mass spectrometry runs (Table 1 and Supplementary Data 4). All the measured precursor masses of the identified Src peptides were within 0.5 ppm of the theoretical masses and the tandem mass spectra (MS/MS) exhibited a continuous stretch of y-ion series, and clear peak assignments, indicating confident identifications (Supplementary Data 5). These analyses revealed Cys-277 and Cys-185 as the most prominently oxidized cysteines, consistent with previous trapping experiments. In case of Cys-277, distinct peaks were observed for dim-d6 and dim-d0 peptide ion isotopologues in the MS1 spectrum (Fig. 1a). Extracted chromatograms for dim-d6 and dim-d0 labeled ions (Fig. 1b red and black, respectively) enabled the determination of heavy to light (H/L) dimedone tagging ratios indicating the degree of cysteine oxidation compared to nonoxidized controls. MS/MS fragmentation spectra of dim-d6 and dim-d0 dimedone labeled Cys-277-containing peptide ions confirmed the identity of this peptide with expected Cys-S-dim-d0/6 isotope-dependent mass shifts (Supplementary Fig. 5C, D). Similar analysis was performed for Cys-185 (Supplementary Fig. 5E–H) and the other cysteine-containing peptides (Table 1 and Supplementary Data 4). Although these analyses also suggested increased sulfenylation of other cysteines, as indicated by H/L ratios >1, these observations were considered less robust based on the high variance (standard deviation (SD)) between triplicate replicates (Table 1 and Supplementary Data 4). Collectively, these analyses indicate that Cys-185 and Cys-277 were consistently identified as the main redox-sensitive cysteines within Src that form detectable Cys-SOH species by H2O2. Previous reports have implicated Cys-277, and other cysteines (e.g., Cys-245 and Cys-498,) as redox-sensitive cysteines in the context of ROS signaling, while Cys-185 has yet to be identified in such mechanisms. The structure of autoinhibited Src (PDB ID: 2SRC) reveals that Cys-185 and Cys-277 reside near (~5–10 Å) pTyr-527 and Tyr-416, respectively, possibly indicating that their oxidation may directly impact these critical regulatory tyrosines (Supplementary Figs. 1B and 6). In contrast, Cys-245 and Cys-498 are distant from these tyrosines (~20–30 Å) and located in regions that are not significantly altered during Src activation. From these considerations, our subsequent studies focused on the role of Cys-185 and Cys-277 oxidation in regulating Src activation.

We evaluated tyrosine kinase activity of recombinant Src in the presence of H2O2 and, consistent with previous studies,, observed that kinase activity of wild-type Src is enhanced linearly and correlated with H2O2 in a dose-dependent manner, ranging between 10 and 30 µM (Fig. 2b and Supplementary Fig. 7), although higher H2O2 concentrations (>100 µM) did not enhance and even inhibited activity (Supplementary Fig. 8). In contrast, H2O2 was incapable of statistically increasing activity of C185A or C277A Src variants, while both retained significant kinase activity. It is important to note that, while the absolute H2O2 concentrations in these studies were lower than those in the MS analyses, the relative molar excess of H2O2 over Src was considerably greater (necessary to overcome the high concentrations of DTT). In any case, these results indicate that H2O2 can directly enhance intrinsic Src tyrosine kinase activity, which is dependent on both Cys-185 and Cys-277, and consistent with these residues being the most susceptible to sulfenylation by H2O2.

Cys-185 and Cys-277 are critical for Src activation in cells

We next addressed the impact of Cys-185 and Cys-277 on H2O2-mediated Src activation in epithelial cells. H292 mucoepidermoid epithelial cells were either transiently or stably transfected with C-terminal FLAG-tagged Src (Src-FLAG) or Cys mutant Src constructs, and activation of Src-FLAG was assessed in response to stimulation with ATP to enhance cellular H2O2 production by activation of the NADPH oxidase DUOX1,,, by monitoring Src (auto)phosphorylation at Tyr-416. While these cells express endogenous Src, we confirmed that expressed Src-FLAG protein is distributed similarly with the cells (Supplemental Fig. 9), and is efficiently purified with M2 anti-FLAG methodologies (Supplemental Fig. 10). As expected,, ATP stimulation of H292 cells expressing WT Src-FLAG resulted in its enhanced phosphorylation at Tyr-416 (Fig. 3, Supplementary Figs. 11–13). No significant changes were observed in Src phosphorylation at pTyr-527 (Supplementary Fig. 13), suggesting that ATP-mediated activation of Src might occur independent of pTyr-527 dephosphorylation. Comparative ATP stimulation of H292 cells expressing either C185A or C277A Src-FLAG variants showed reduced Tyr-416 phosphorylation within these proteins (Fig. 3 and Supplementary Figs. 11, 13), indicating that these proteins were not activated in response to cellular H2O2 production. To associate these observations with cysteine oxidation, cells expressing WT, C185A, and C277A Src-FLAG were preloaded with the alkyne derivative of dimedone (DYn-2) prior to stimulation. Following lysis, DYn-2-tagged proteins were conjugated to biotin-azide by click-mediated ligation and purified with M2 anti-FLAG antibodies, to visualize formation of Cys-SOH within Src-FLAG variants by streptavidin-horseradish peroxidase (HRP) blotting. Consistent with previous studies, ATP stimulation induced sulfenylation within WT Src, whereas sulfenylation was dramatically attenuated in C185A and C277A variants (Fig. 3 and Supplementary Figs. 11, 12), indicating that both Cys-185 and Cys-277 are sulfenylated during DUOX1-dependent activation of Src. Alternatively, ATP-stimulated H292 cells expressing Src-FLAG proteins were derivatized during cell lysis with biotin-conjugated dimedone (DCP-Bio1), after which Src-FLAG proteins were purified and analyzed for pTyr-416 or biotin incorporation, which yielded highly similar results (Supplementary Fig. 13). These collective findings indicate that Src is redox regulated within a cellular context and that both Cys-185 and Cys-277 are sulfenylated in response to DUOX1-mediated H2O2 production and are critical for Src activation.

MD simulations reveal structural alterations by sulfenylation

Activation of Src involves significant structural alterations, but it is unclear how sulfenylation of specific cysteines impact on kinase activation. To address this, we performed both microsecond-long MD simulations and metadynamics simulations to assess the structural perturbations induced by substitution of Cys-185 and Cys-277 in the autoinhibited Src structure with their sulfenylated form, Cys-SOH. It is not intuitive how such a small modification would induce significant structural alterations, but recent MD simulations indicate significant impact of sulfenylation of specific cysteines in other proteins,. As Cys-SOH is a weak acid, it may also be deprotonated (Cys-SO−). Various Cys-SOH pKa estimates indicate values ranging from 6 to 10 in the context of small molecules,, consistent with density-functional theory calculations of model compounds (see Supplementary computational methods). Recent estimates in dipeptides and selected proteins indicate pKa values for Cys-SOH of ~5.9–7.2,, implying that a significant fraction of Cys-SOH exist in its protonated state under physiological conditions. Based on this, and the fact that previous MD simulations of Cys-SOH indicated structural changes when modeling the protonated state,, we performed our MD simulations based on protonated forms of Cys-SOH as well as Cys-SH. To incorporate the Cys-SOH into these MD simulations, we derived and benchmarked CHARMM36-compatible force field parameters for the cysteine sulfenic acid (cysteine sulfenic acid force field parameters in Supplementary Methods and Supplementary Fig. 14).

We first simulated the effect of Cys-SOH at Cys-277, which is located on the solvent-accessible G-rich loop and within ~10 Å from Tyr-416 on the A-loop α-helix. The wild-type inactive Src structure (PDB ID: 2SRC), and other systems in which Cys-277 is reduced (Cys-SH), were considered control structures for comparing structural changes induced by Cys-277-SOH. The A-loop (residues 406–423), which consists of two helical segments (residues 407–410 and 414–418), remains folded throughout the MD simulations of all control structures (Supplementary Fig. 15; Supplementary Movie 1). In contrast, when Cys-277-SH was substituted with Cys-277-SOH, a significant loss in A-loop helicity was observed in both simulations of 5 µs (Fig. 4b). One of these simulations showed rapid unfolding of the A-loop (#1 in Fig. 4b; Supplementary Movie 2), while the other underwent a slower process with major unfolding in the segment of res. 407–410 (#2 in Fig. 4b). These findings suggest that Cys-277-SOH-dependent A-loop unfolding is complex and involves multiple paths. Focusing on the interactions around the A-loop, we analyzed these two Cys-277-SOH simulations and the other six control simulations (all Cys-SH, Cys-185-SOH, and Cys-498-SOH). In control groups, the key regulatory Tyr-416 resides near or within H-bonding distance with Asp-386 of loop residues 383–389, with the side-chain phenol positioned away from solvent and within the catalytic cleft (Supplementary Fig. 15B). Additionally, these simulations identified another possible key residue, Arg-419, which occasionally swings to interact with Asp-386. Cys-277-SOH likely competes with Tyr-416 for H-bonding interactions with Asp-386 and a result of sulfenylation of Cys-277, interaction of Cys-277-SOH with Asp-386 promotes a shuffle in these residues resulting in pairing of Arg-385 with Asp-444 due to the displacement of loop residues 383–389 (Supplementary Figs. 15A and 16B). Subsequently, Arg-419 is able to pair with Asp-386, enabling the exposure of Tyr-416 to solvent making it accessible for phosphorylation.

The impact of Cys-277-SOH on A-loop unfolding is further evident from the free-energy landscapes obtained from metadynamics simulations (Fig. 4c). According to the interactions revealed from the above MD simulations, we chose the pair distances of (Tyr-416)–(Asp-386) and (Arg-419)–(Asp-386) as collective variables (CVs) and performed metadynamics simulations on the Cys-277-SOH and wild-type (Cys-277-SH) systems, respectively. Large increases of these pair distances due to sulfenylation of Cys-277 would be expected to lead to unfolding of the A-loop, thus further confirming the impact of Cys-277-SOH on A-loop unfolding. In the wild-type structure, the lowest free-energy conformation is found when Tyr-416 is ~5 Å from Asp-386 and Arg-419 is ~15 Å from Asp-386. However, when Cys-277 is replaced with Cys-SOH, the lowest free-energy conformations appear in two areas: a small region that is similar to the wild-type and a larger region where both Tyr-416 and Arg-419 are at significantly longer distances of 17–22 Å from Asp-386. This latter “long-distance” conformation corresponds to the unfolded A-loop structure (yellow in Fig. 4a), which is energetically favorable. Results from these simulations, therefore, indicate that Cys-277-SOH induces activation of the kinase by promoting rapid and thermodynamically favorable unfolding of the A-loop and solvent exposure of Y416 for phosphorylation.

Next, we simulated the effect of sulfenylation of Cys-185, located within the SH2 domain near the regulatory active site that binds pTyr-527 located on the Src C-terminal tail. Simulations of reduced Cys-185-SH show that pTyr-527 forms H-bonds with Arg-175 and Arg-155, while Cys-185-SH, at a distance of ~4–6 Å away from pTyr-527 or Arg-175, is otherwise noninteracting with these residues (Supplementary Fig. 16A, Supplementary Movie 3). In contrast, when Cys-185-SH is substituted for Cys-185-SOH, it now engages in H-bonding with the phosphate moiety of pTyr-527 (Fig. 5a and Supplementary Movie 4). We did not observe full dissociation of pTyr-527 within the limited length of our simulations, but dissociation may be indicated by the increasing number of water solvent contacts with pTyr-527 induced by sulfenylation of Cys-185 as compared with reduced (Cys-185-SH) states (Fig. 5b), and such increased solvent exposure of pTyr-527 may enhance access to tyrosine phosphatases that promote its dephosphorylation and Src unclamping.

In line with these conventional simulations, metadynamics simulations revealed that Cys-185-SOH significantly alters the free-energy landscape of pTyr-527 binding to the SH2 domain. In these simulations, we chose pair distances of (pTyr-527)–(Arg-175) and (pTyr-527)–(Arg-155) as CVs, since these positive arginine side chains enable tight electrostatic binding of the negative pTyr-527 and observed increases in distances would model the dissociation of pTyr-527 from the SH2 domain. In wild-type Src (Cys-185-SH), the lowest free-energy conformation is observed when pTyr-527 is located nearby (~4–6 Å) Arg-175 and Arg-155 (Fig. 5c right), consistent with the structure of autoinhibited Src. In contrast, when Cys-185 is present as a sulfenic acid, the lowest free-energy conformation is located where pTyr-527 is completely dissociated from the SH2 domain, at a distance of 13–18 Å from Arg-175 and Arg-155 (yellow in Fig. 5a and Fig. 5c left). These findings further support the notion that oxidation of Cys-185-SH to Cys-185-SOH critically destabilizes the binding of the autoinhibitory pY527 in a mechanism where first solvent accessibility to pTyr-527 is enhanced via hydrogen bonding eventually leading to complete exergonic dissociation from the SH2 domain.

Finally, since our mass spectrometry analysis also indicated sulfenylation at Cys-498 (Supplementary Table 2), we also carried out simulations of two replicas of Cys-498-SOH for a total of 10 µs. However, only subtle conformational changes were observed at the helical bundles near Cys-498 (Supplementary Fig. 17A, B), and metadynamics simulations show comparable energy basins for the Cys-498-SH and Cys-498-SOH systems (Supplementary Fig. 17C). These findings together indicate minimal structural impact of Cys-498-SOH within the C-lobe, and thus a minimal direct role for Cys-498 oxidation for Src kinase activation.

Discussion

While several studies have suggested that the Src kinase is regulated by direct redox mechanisms, the identity of the redox-sensitive cysteine residues and the mechanism(s) by which their oxidation impacts kinase activation are unknown,. Following our recent findings indicating that redox-dependent activation of Src in biochemical and cellular contexts closely associates with formation of sulfenic acids (Cys-SOH) within Src,, we now identify Cys-185 and Cys-277 as the main cysteines oxidized to Cys-SOH by H2O2 and demonstrate that sulfenylation of both cysteines contribute to H2O2-dependent enhancement of Src kinase activity based on combined experimental and computational studies. Recent MD simulation studies have indicated significant structural consequences of sulfenylation of specific cysteines in proteins, e.g., EGFR and monoacylglycerol lipase, which are structurally distinct from Cys-185 or Cys-277 in Src. Interestingly, the structural alterations characterized in these MD simulations were attributed to the introduction of electrostatic interactions with nearby amino acids upon formation of a sulfenic acid, consistent with our present studies, which similarly indicate that sulfenylation of Cys-185 and Cys-277 induces altered electrostatic interactions through H-bonding within their respective domains.

Combined crystallography and computational modeling have generated a molecular model for Src kinase activation, involving initial conversion of the autoinhibited kinase to a Tyr-416 unphosphorylated active-like state and subsequent phosphorylation of Tyr-416 resulting in stabilization of the active kinase,,,. Our findings indicating Cys-185 and Cys-277 as principal redox-active targets, and their proximity to regulatory tyrosine residues, respectively Tyr-527 and Tyr-416, suggests that their oxidation directly modulates activation. Cys-277 resides on the solvent-accessible G-rich loop near the A-loop, and is solvent accessible. Computational studies using Markov state models by Roux and colleagues highlight A-loop unfolding as the first step on the pathway to the active-like state, occurring on a time scale of ~100 µs,. These modeling studies were based on simulations of the Src kinase domain in the absence of the SH2/3 domains. Importantly, our conventional and metadynamics simulations of the entire autoinhibited Src protein show that Cys-277-SOH destabilizes the folded A-loop containing Y416 toward a more favorable unfolded state on a shorter (~1.5–3.5 µs) timescale, which would imply that oxidation of Cys-277 accelerates the conversion to the active-like state, which is potentially stabilized in the absence of Tyr-416 phosphorylation (Fig. 4). Our MD simulations also indicate that Cys-277-SOH induces A-loop unfolding in the absence of other activating structural changes, such as SH2/3 domain dissociation and αC-helix rotation, which is expected to occur at longer time scales. The importance of Cys-185 in redox regulation of Src activity has not been recognized previously, although it was recently implicated in substrate binding through intermolecular disulfide bonding. This cysteine residue is unique in Src, since all other SFKs contain a serine at the corresponding position (Supplementary Table 1), but proximally located cysteines are found within the phosphotyrosine binding region of other SH2 domains. Previous work has shown that Ala and Ser variations of Cys-185 result in tighter binding of phosphorylated peptides, suggesting that Cys-185-SH modifications impact the binding of the autoinhibitory pTyr-527. Our MD simulations indicating that Cys-185-SOH significantly destabilizes pY527 binding to the SH2 domain (Fig. 5) would suggest that sulfenylation of Cys-185 prevents autoinhibition of Src by lowering the binding affinity of pY527 to the SH2 domain. Additionally, it should be noted that Cys-185 within the autoinhibited structure is obscured from solvent, which limits its accessibility by H2O2, but is expected to be redox-active due to its proximity to the positive Arg-175. Since Cys-185 is solvent exposed in activated Src (PDB ID 1Y57), it is more likely that oxidation of Cys-185 occurs in cooperation with dissociation of pTyr-527 by alternative mechanisms, and thereby enhances or prolongs Src activation.

Our collective experimental and molecular modeling studies have led us to propose a step-wise mechanism for the regulation of Src activity by oxidation of Cys-185 and Cys-277 (Fig. 6). Based on our experimental findings indicating Cys-277 as the primary oxidizable cysteine, we propose that initial oxidation of Cys-277-SH triggers the structural conversion of the autoinhibited state to an active-like state by destabilizing the A-loop helical fold allowing for the exposure of Tyr-416 for phosphorylation. Further structural changes in Src activation, such as rotation of the αC-helix, likely proceed from this state although they were not observed in our MD simulations as they are computed to be beyond our time scale. These structural changes put the kinase into an active-like state in the absence of pTyr-527 dephosphorylation, since the structural changes promoting A-loop unfolding occurred in the absence of dissociation of the autoinhibitory loop and unclamping of the Src protein (Fig. 6 middle). We suggest that unfolding of the A-loop by Cys-277 oxidation may induce semi-“unclamping” of the SH2/3 domains, as the binding of these domains are coupled to the fold of the A-loop,,, thereby enhancing solvent accessibility of Cys-185 to H2O2 and facilitating its oxidation. Formation of Cys-185-SOH in turn enhances solvent accessibility of pY527, based on our metadynamics simulations, to promote full dissociation of pY527 from the SH2 domain. Although not addressed in the present study, Cys-SOH species readily reacts with cellular thiols such as glutathione (GSH) to form mixed disulfides (e.g., S-glutathionylated cysteine, Cys-SSG), and our previous studies indicate that H2O2-mediated activation of Src is associated with sequential formation of Cys-SOH and Cys-SSG,. Although S-glutathionylation may not directly activate Src, we propose that formation of Cys-SSG species on Cys-185 or Cys-277 would induce steric and electrostatic alterations that may enhance structural perturbations. For example, Cys-185-SSG is expected to preclude inactivating interaction of pTyr-527 with the SH2 domain, thereby extending redox-dependent Src activation until Cys-185-SSG is reduced by, e.g., glutaredoxins (Fig. 6 right). Our model therefore suggests that Src activity is controlled by sulfenylation of both Cys-185 and Cys-277 in a cooperative and dynamic mechanism, after which subsequent S-glutathionylation both extends Src activation and facilitates reversal to the inactive state by glutaredoxin-mediated regeneration of reduced cysteines.

It is important to highlight some limitations of our present studies. First, our MD simulations were based on protonated forms of Cys-SOH, as this is the initial product of reaction of Cys-S− with H2O2 justified by benchmarked pKa values for simple models due to the variability in experimental estimates., However, in light of more recent biochemical estimates of the Cys-SOH pKa nearer or below physiological pH,, we cannot rule out that Cys-SOH may also exist in its deprotonated state (or dynamic equilibrium mixture) due to unique and yet uncharacterized second sphere coordination environments of the specific redox-active cysteine residues reported in this work and is the subject of ongoing studies in our labs. We do anticipate that the more anionic Cys-SO− would induce alternative or additional structural changes. Another limitation is that this study did not address the role of other Src Cys residues implicated in previous studies,,. Our MS studies indeed indicate that other cysteines (e.g., Cys-238, Cys-498) may also be oxidized to Cys-SOH. Moreover, our relative inability to trap Cys-SOH with either dimedone or BCN on these other cysteines does not necessarily mean that these cysteines are not oxidized, but might instead be a result of their rapid condensation to disulfide species. Indeed, studies with recombinant Src indicated the formation of DTT-reducible higher molecular weight species in the presence of high doses of H2O2 reflecting formation of inter- or intramolecular disulfides. Chiarugi and co-workers suggested that redox-dependent Src activation during cell adhesion depends on the presence of Cys-245 and Cys-487 and proposed that oxidation of these cysteines may induce structural alterations via an intramolecular disulfide, although this seems highly unlikely based on long distances (~30–60 Å) between these cysteine residues in existing structures. Other studies have implicated Cys-498 as a target for S-nitrosylation in activation of Src, although the molecular mechanism was not addressed. Our MD simulations of Cys-498-SOH indicate minimal structural changes in the kinase domain C-lobe, but since Cys-498 is located near the myristate binding pocket within the Src kinase domain, it is plausible that oxidation of Cys-498 might interfere with Src myristoylation. Alternatively, it is possible that these alternative Cys oxidations may regulate Src-dependent signaling in a cellular context by enhancing interactions with regulatory proteins or substrates through, e.g., disulfides, as was recently demonstrated for Cys-185, rather than by inducing structural transitions that would promote intrinsic kinase activity. Finally, the field of thiol-based redox signaling has recently recognized that protein cysteines can also exist in the form of persulfides (i.e., Cys-SSn-H). Indeed, we recently reported that cellular Src may also contain Cys-SSn-H species, which are more susceptible to oxidation compared to corresponding cysteines. The functional consequences of such persulfide oxidation for Src activation are unclear and not addressed in this study, since our experimental approaches included DTT, which would have eliminated such (oxidized) polysulfides prior to analysis. Addressing the relevance of such (oxidized) polysulfide species would require additional technically challenging experimental approaches and alternative MD simulations.

In summary, we demonstrate that the redox-dependent regulation of the Src kinase involves protein structural alterations induced by the oxidation of two cysteine residues, Cys-185 and Cys-277, to intermediate sulfenic acids. Cys-277 is conserved in other SFKs such as Yes and Fgr, which may be subject to similar redox-dependent activation, but Cys-185 is not found in other SFKs (Supplementary Table 1). Therefore, the redox-dependent mechanisms of kinase activation may be unique to Src compared to other SFKs, and may be informative with respect to drug development efforts toward selective Src inhibitors. Current Src inhibitors in clinical development are relatively non-selective since they target the kinase ATP-binding pocket. Efforts to develop covalent Src-selective inhibitors targeting Cys-277 enhance selectivity, but may be compromised upon oxidation of Cys-277. Instead, approaches to target the oxidized states of these cysteines may enhance efficacy and selectivity. Finally, targeting of oxidant-induced structural changes with allosteric inhibitors, as opposed to ATP competitive inhibitors, may offer further selectivity for situations with pathologically elevated ROS. Therefore, a more complete understanding of the molecular details of redox-dependent mechanisms of the SFKs as well as other redox-sensitive kinases, may offer exciting new directions for drug discovery.

Src expression and purification

Recombinant Src and variants were expressed in BL21-AI Escherichia coli (Thermo) containing the pEX-Src-C-His (Origene, Blue Heron Biotech) and purified in a modified procedure as previously described (see Supplementary methods for complete details).

Mass spectrometry

Recombinant Src (~20 µg in dimedone experiments, ~13 µg in BCN experiments, final DTT concentration 0.03–0.25 mM) was incubated with either 1.0 mM 5,5′-dimethyl-1,3-cyclohexanedione (dimedone; Sigma), 100 µM 9-hydroxymethylbicyclo[6.1.0.]nonyne (BCN, Sigma), or 5 mM 4-chloro-7-nitrobenzofuran (NBD-Cl), and then reacted with 0–1.0 mM H2O2 (Sigma) for 1 h at 25 °C. For quantitative analysis of sulfenylation, Src (~20 µg) was reacted with 0 or 1.0 mM H2O2 in the presence of light (d0) or heavy (d6) dimedone, respectively, for 1 h, followed by catalase quenching. A 1:1 mixture of d0 and d6 labeled samples was run on 10% SDS-PAGE gels and protein bands were excised, washed, and trypinized (Promega V511A). Peptides were reconstituted with 2.5% CH3CN/2.5% formic acid and analyzed by capillary LC–MS/MS on a LTQ (for initial studies with dimedone and NBD-Cl) or a Q-Exactive mass spectrometer coupled to an EASY-nLC (Thermo Fisher Scientific, Waltham, MA, USA). Product-ion spectra were searched using the SEQUEST search engine implemented on the Proteome Discoverer 1.4 (Thermo Fisher). Percolator node was included in the workflow to limit false-positive rates to less than 1% in the data sets. Scaffold 4.05 (Proteome Software) was used for sequence annotation. For experiments involving quantification of dimedone-d0 and dimedone-d6 labeled peptides, targeted mass spectrometry experiments were performed. MS data were acquired with alternating MS–SIM scans and PRM (two scan groups in the Method). Search files (.msf) were then imported into Skyline for selecting the precursor or transitions for quantitation. Four to six transitions were selected from, if possible, the third to the last fragment ions in the product-ion spectrum for quantification. Boundaries of integration were manually evaluated.

Tyrosine kinase activity measurements

Tyrosine kinase activity of recombinant Src (1 ng in 15 µL with 2.0 mM DTT) was analyzed using the ADP-Glo (Promega) assay kit according to the manufacture’s protocol in a final reaction volume of 25 μL (Supplementary Information). Src was treated with H2O2 (Thermo) for 15 min prior to initiating catalysis for 60 min at 25 °C within the linear kinetic range. Reactions were measured for luminescence and specific activity values were obtained from an ADP (Promega) linear standard curve.

H292 cell transfection with Src-FLAG constructs

Src-FLAG constructs were transiently transfected into NCI-H292 pulmonary mucoepidermoid cells (ATCC) at 85–90% confluence using the Turbofect reagent (Thermo) according to a modified version of the manufacturer’s protocol. Briefly, 1 µg of pCMV6-Src (Origene) was mixed with 8 µL Turbofect and 100 µL serum-free RPMI media (per well) and allowed to incubate at RT for 20 min. Cells were changed to 900 µL serum-free media prior to dropwise addition of 100 µL transfection mix. Cells were then incubated at 37 °C for 24 h, followed by PBS washing and 24 h of full RPMI. Prior to experiments (~48–72 h post-transfection), cells were switched to serum-free RPMI for overnight incubation. H292 cell lines stably expressing C-terminal FLAG-tagged Src were generated by transfecting ~70% confluent cells with 1 µg of DNA from the pCMV6-Src (Origene) and 2 µL of Turbofect Transfection reagent (Fisher) in RPMI media for 24 h as per manufacture’s protocol, and selection over 10–15 days in serum containing media with 150 µg/mL of neomycin (G418; Calbiochem).

Cell culture and treatments

NCI-H292 cells, a human pulmonary mucoepidermoid carcinoma cell line, were originally obtained from the American Type Culture Collection (ATCC), grown in RPMI 1640 medium containing 10% fetal bovine serum and 1% penicillin/streptomycin at 37 °C and 5% CO2, seeded at 100,000 cells/well in 24-well plates (Corning), and serum starved overnight., For in situ analysis of protein sulfenylation (−SOH), cells were preloaded with 5 mM DYn-2 reagent (Kerafast) for 15–30 min, and subsequently stimulated with ATP (Sigma, St. Louis, MO; 100 µM) for 10 min. Cells were then lysed in chelator-free HEPES lysis buffer and clicked to biotin-azide (Kerafast) using established protocols (Supplementary Information). As an alternative approach to detect sulfenylated proteins, cells were lysed with western solubilization buffer containing 1 mM DCP-bio1 (Kerafast), as described previously,. FLAG-tagged Src and mutants were purified using Anti-FLAG M2 magnetic beads (Sigma) and eluted with 3× FLAG peptide (Sigma) as per manufacture’s protocol (Supplementary Information).

Western blotting

Derivatized cell lysates were separated by 10% SDS-PAGE gels and transferred to nitrocellulose membranes, and probed using antibodies against p-Src Tyr 416 (1:400; 2101S), p-Src Tyr 527 (1:400; 2105S), Src (L4A1; 1:1000; 2110S), FLAG (DDK; 1:1000; 2368S) (Cell Signaling), or streptavidin peroxidase polymer ultrasensitive (1:10,000; S2438; Sigma). Primary antibodies were probed with rabbit- or mouse-specific secondary antibodies conjugated with HRP (Cell Signaling) and detected by enhanced chemiluminescence (Pierce). Membranes were imaged with Amersham Imager 600 (GE Healthcare) and band densities were quantified using ImageQuant TL (v8.1.0.0).

MD simulations

All molecular dynamics and metadynamics simulations were performed with the CHARMM36 force field in addition to our customized parameters for the cysteine sulfenic acid (Cys-SOH). The parameters (i.e., for bonds, angles, and dihedral angles) and partial charges for cysteine sulfenic acid were validated or modified according to the density-functional theory calculations with B3LYP/6-31g** in Jaguar, (see Cysteine sulfenic acid force field parameters of Supplementary methods). The protein models were constructed from the autoinhibited Src structure (PDB ID: 2SRC). A web-based graphical user interface CHARMM-GUI was used to prepare the initial models for simulations, which contain our protein models, 17,000–26,000 TIP3P water molecules, chloride potassium as counter ions, totaling near 58,400–85,400 atoms in a periodic box 85 × 89 × 82–94 × 94 × 94 Å3. After the equilibrium stage for 10 ns in the NAMD program, production runs of conventional MD simulations (for 2–5 µs) were carried out on the specialized ANTON supercomputer using the software program Anton 2.13.0 and with the Desmond program (Schrödinger, Inc.) on graphical processing units (GPUs). Metadynamics simulations were also carried out on GPUs to determine the two-dimensional, free-energy landscapes of conformational transition in the cysteine oxidation region in comparison with corresponding nonoxidized cysteines, using two CVs that were chosen based on conformational changes suggested by the conventional MD simulations. To ensure convergence, we have calculated the free-energy difference every 10 ns after 80 ns: the key energy basins remain to the final 120 ns with a general SD of 0–0.68 kcal/mol for the maximum free-energy difference. A summary of our simulations is provided in Supplementary Table 3.

Statistical analysis

Data are expressed at means ± s.e.m. for the indicated number of observations and comparisons are analyzed with student’s t test or two-way ANOVA.

References 67

  1. 1.

    Yeatman TJ. A renaissance for SRC. Nat. Rev. Cancer. 2004;4:470-480.

    Not in our library10.1038/nrc1366 (opens in a new tab)

  2. 2.

    Luttrell DK, Luttrell LM. Not so strange bedfellows: G-protein-coupled receptors and Src family kinases. Oncogene. 2004;23:7969-7978.

    Not in our library10.1038/sj.onc.1208162 (opens in a new tab)

  3. 3.

    Bromann PA, Korkaya H, Courtneidge SA. The interplay between Src family kinases and receptor tyrosine kinases. Oncogene. 2004;23:7957-7968.

    Not in our library10.1038/sj.onc.1208079 (opens in a new tab)

  4. 4.

    Allgayer H, et al. Activation of Src kinase in primary colorectal carcinoma. Cancer. 2002;94:344-351.

    Not in our library10.1002/cncr.10221 (opens in a new tab)

  5. 5.

    Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat. Rev. Clin. Oncol. 2009;6:587-595.

    Not in our library10.1038/nrclinonc.2009.129 (opens in a new tab)

  6. 6.

    Rivera J, Olivera A. Src family kinases and lipid mediators in control of allergic inflammation. Immunol. Rev. 2007;217:255-268.

    Not in our library10.1111/j.1600-065x.2007.00505.x (opens in a new tab)

  7. 7.

    Wang J, Zhuang S. Src family kinases in chronic kidney disease. Am. J. Physiol. Ren. Physiol. 2017;313:F721-F728.

    Not in our library10.1152/ajprenal.00141.2017 (opens in a new tab)

  8. 8.

    Boggon TJ, Eck MJ. Structure and regulation of Src family kinases. Oncogene. 2004;23:7918-7927.

    Not in our library10.1038/sj.onc.1208081 (opens in a new tab)

  9. 9.

    Xu W, Doshi A, Lei M, Eck MJ, Harrison SC. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol. Cell. 1999;3:629-638.

    Not in our library10.1016/s1097-2765(00)80356-1 (opens in a new tab)

  10. 10.

    Gan W, Yang S, Roux B. Atomistic view of the conformational activation of Src kinase using the string method with swarms-of-trajectories. Biophys. J. 2009;97:L8-L10.

    Not in our library10.1016/j.bpj.2009.06.016 (opens in a new tab)

  11. 11.

    Meng Yilin, Pond Matthew P., Roux Benoît. Tyrosine Kinase Activation and Conformational Flexibility: Lessons from Src-Family Tyrosine Kinases. Accounts of Chemical Research. 2017;50(5):1193-1201.

    Not in our library10.1021/acs.accounts.7b00012 (opens in a new tab)

  12. 12.

    Meng Y, Roux B. Locking the active conformation of c-Src kinase through the phosphorylation of the activation loop. J. Mol. Biol. 2014;426:423-435.

    Not in our library10.1016/j.jmb.2013.10.001 (opens in a new tab)

  13. 13.

    Weir ME, et al. Novel autophosphorylation sites of Src family kinases regulate kinase activity and SH2 domain‐binding capacity. FEBS Lett. 2016;590:1042-1052.

    Not in our library10.1002/1873-3468.12144 (opens in a new tab)

  14. 14.

    Giannoni E, Chiarugi P. Redox circuitries driving Src regulation. Antioxid. Redox Signal. 2014;20:2011-2025.

    Not in our library10.1089/ars.2013.5525 (opens in a new tab)

  15. 15.

    Holmstrom KM, Finkel T. Cellular mechanisms and physiological consequences of redox-dependent signalling. Nat. Rev. Mol. Cell Biol. 2014;15:411-421.

    Not in our library10.1038/nrm3801 (opens in a new tab)

  16. 16.

    Jones DP, Sies H. The redox code. Antioxid. Redox Signal. 2015;23:734-746.

    Not in our library10.1089/ars.2015.6247 (opens in a new tab)

  17. 17.

    Tonks NK. Redox redux: revisiting PTPs and the control of cell signaling. Cell. 2005;121:667-670.

    Not in our library10.1016/j.cell.2005.05.016 (opens in a new tab)

  18. 18.

    Corcoran A, Cotter TG. Redox regulation of protein kinases. FEBS J. 2013;280:1944-1965.

    Not in our library10.1111/febs.12224 (opens in a new tab)

  19. 19.

    Truong TH, Carroll KS. Redox regulation of protein kinases. Crit. Rev. Biochem. Mol. Biol. 2013;48:332-356.

    Not in our library10.3109/10409238.2013.790873 (opens in a new tab)

  20. 20.
  21. 21.

    Paulsen CE, et al. Peroxide-dependent sulfenylation of the EGFR catalytic site enhances kinase activity. Nat. Chem. Biol. 2012;8:57-64.

    Not in our library10.1038/nchembio.736 (opens in a new tab)

  22. 22.

    Sham D, Wesley UV, Hristova M, van der Vliet A. ATP-mediated transactivation of the epidermal growth factor receptor in airway epithelial cells involves DUOX1-dependent oxidation of Src and ADAM17. PLoS One. 2013;8:e54391.

    Not in our library10.1371/journal.pone.0054391 (opens in a new tab)

  23. 23.

    Matsushima S, et al. Tyrosine kinase FYN negatively regulates NOX4 in cardiac remodeling. J. Clin. Invest. 2016;126:3403-3416.

    Not in our library10.1172/jci85624 (opens in a new tab)

  24. 24.

    Hristova M, et al. Airway epithelial DUOX1 mediates allergen-induced IL-33 secretion and activation of type 2 immune responses. J. Allergy Clin. Immunol. 2016;137:1545-1556.

    Not in our library10.1016/j.jaci.2015.10.003 (opens in a new tab)

  25. 25.

    Heppner DE, et al. The NADPH oxidases DUOX1 and NOX2 play distinct roles in redox regulation of epidermal growth factor receptor signaling. J. Biol. Chem. 2016;291:23282-23293.

    Not in our library10.1074/jbc.m116.749028 (opens in a new tab)

  26. 26.

    Habibovic A, et al. DUOX1 mediates persistent epithelial EGFR activation, mucous cell metaplasia, and airway remodeling during allergic asthma. JCI Insight. 2016;1:e88811.

    Not in our library10.1172/jci.insight.88811 (opens in a new tab)

  27. 27.

    Truong Thu H, Ung Peter MU, Palde Prakash B, Paulsen Candice E, Schlessinger A, Carroll Kate S. Molecular basis for redox activation of epidermal growth factor receptor kinase. Cell Chem. Biol. 2016;23:837-848.

    Not in our library10.1016/j.chembiol.2016.05.017 (opens in a new tab)

  28. 28.

    Oo ML, et al. Cysteine residues in the C-terminal lobe of Src: their role in the suppression of the Src kinase. Oncogene. 2003;22:1411-1417.

    Not in our library10.1038/sj.onc.1206286 (opens in a new tab)

  29. 29.

    Giannoni E, Buricchi F, Raugei G, Ramponi G, Chiarugi P. Intracellular reactive oxygen species activate Src tyrosine kinase during cell adhesion and anchorage-dependent cell growth. Mol. Cell. Biol. 2005;25:6391-6403.

    Not in our library10.1128/mcb.25.15.6391-6403.2005 (opens in a new tab)

  30. 30.

    Kemble DJ, Sun G. Direct and specific inactivation of protein tyrosine kinases in the Src and FGFR families by reversible cysteine oxidation. Proc. Natl Acad. Sci. USA. 2009;106:5070-5075.

    Not in our library10.1073/pnas.0806117106 (opens in a new tab)

  31. 31.

    Senga T, et al. The cysteine-cluster motif of c-Src: its role for the heavy metal-mediated activation of kinase. Cancer Sci. 2008;99:571-575.

    Not in our library10.1111/j.1349-7006.2007.00714.x (opens in a new tab)

  32. 32.

    Zhang H, Davies KJ, Forman HJ. TGFβ1 rapidly activates Src through a non-canonical redox signaling mechanism. Arch. Biochem. Biophys. 2015;568:1-7.

    Not in our library10.1016/j.abb.2015.01.001 (opens in a new tab)

  33. 33.

    Paulsen CE, Carroll KS. Cysteine-mediated redox signaling: chemistry, biology, and tools for discovery. Chem. Rev. 2013;113:4633-4679.

    Not in our library10.1021/cr300163e (opens in a new tab)

  34. 34.

    Heppner DE, Janssen-Heininger YMW, van der Vliet A. The role of sulfenic acids in cellular redox signaling: reconciling chemical kinetics and molecular detection strategies. Arch. Biochem. Biophys. 2017;616:40-46.

    Not in our library10.1016/j.abb.2017.01.008 (opens in a new tab)

  35. 35.

    Poole TH, et al. Strained cycloalkynes as new protein sulfenic acid traps. J. Am. Chem. Soc. 2014;136:6167-6170.

    Not in our library10.1021/ja500364r (opens in a new tab)

  36. 36.

    McGarry DJ, Shchepinova MM, Lilla S, Hartley RC, Olson MF. A cell-permeable biscyclooctyne as a novel probe for the identification of protein sulfenic acids. ACS Chem. Biol. 2016;11:3300-3304.

    Not in our library10.1021/acschembio.6b00742 (opens in a new tab)

  37. 37.

    Galardon E, Padovani D. Reactivity of persulfides toward strained bicyclo[6.1.0]nonyne derivatives: relevance to chemical tagging of proteins. Bioconjug. Chem. 2015;26:1013-1016.

    Not in our library10.1021/acs.bioconjchem.5b00243 (opens in a new tab)

  38. 38.

    Gupta V, Carroll KS. Profiling the reactivity of cyclic C-nucleophiles towards electrophilic sulfur in cysteine sulfenic acid. Chem. Sci. 2016;7:400-415.

    Not in our library10.1039/c5sc02569a (opens in a new tab)

  39. 39.

    Conte ML, Carroll KS. The redox biochemistry of protein sulfenylation and sulfinylation. J. Biol. Chem. 2013;288:26480-26488.

    Not in our library10.1074/jbc.r113.467738 (opens in a new tab)

  40. 40.

    Seo YH, Carroll KS. Quantification of protein sulfenic acid modifications using isotope-coded dimedone and iododimedone. Angew. Chem. 2011;123:1378-1381.

    Not in our library10.1002/ange.201007175 (opens in a new tab)

  41. 41.

    Krasnowska EK, et al. N-acetyl-l-cysteine fosters inactivation and transfer to endolysosomes of c-Src. Free Radic. Biol. Med. 2008;45:1566-1572.

    Not in our library10.1016/j.freeradbiomed.2008.09.012 (opens in a new tab)

  42. 42.

    Hristova M, et al. Identification of DUOX1-dependent redox signaling through protein S-glutathionylation in airway epithelial cells. Redox Biol. 2014;2:436-446.

    Not in our library10.1016/j.redox.2013.12.030 (opens in a new tab)

  43. 43.

    Scalvini L, et al. Free-energy studies reveal a possible mechanism for oxidation-dependent inhibition of MGL. Sci. Rep. 2016;6:31046.

    Not in our library10.1038/srep31046 (opens in a new tab)

  44. 44.

    Tadashi O, et al. Equilibrium and kinetic studies of reactions of 2-methyl-2-propanesulfenic acid. Heteroat. Chem. 1992;3:577-583.

    Not in our library10.1002/hc.520030520 (opens in a new tab)

  45. 45.

    Nagy P, Ashby MT. Reactive sulfur species: kinetics and mechanisms of the oxidation of cysteine by hypohalous acid to give cysteine sulfenic acid. J. Am. Chem. Soc. 2007;129:14082-14091.

    Not in our library10.1021/ja0737218 (opens in a new tab)

  46. 46.

    Portillo-Ledesma S, et al. Differential kinetics of two-cysteine peroxiredoxin disulfide formation reveal a novel model for peroxide sensing. Biochemistry. 2018;57:3416-3424.

    Not in our library10.1021/acs.biochem.8b00188 (opens in a new tab)

  47. 47.
  48. 48.

    Tong M, et al. Survey of solution dynamics in Src kinase reveals allosteric cross talk between the ligand binding and regulatory sites. Nat. Commun. 2017;8:2160.

    Not in our library10.1038/s41467-017-02240-6 (opens in a new tab)

  49. 49.

    Meng Y, Shukla D, Pande VS, Roux B. Transition path theory analysis of c-Src kinase activation. Proc. Natl Acad. Sci. 2016;113:9193-9198.

    Not in our library10.1073/pnas.1602790113 (opens in a new tab)

  50. 50.

    Evans JV, et al. Src binds cortactin through an SH2 domain cystine-mediated linkage. J. Cell Sci. 2012;125:6185-6197.

    Not in our library10.1242/jcs.121046 (opens in a new tab)

  51. 51.

    Bradshaw JM, Mitaxov V, Waksman G. Investigation of phosphotyrosine recognition by the SH2 domain of the Src kinase1. J. Mol. Biol. 1999;293:971-985.

    Not in our library10.1006/jmbi.1999.3190 (opens in a new tab)

  52. 52.

    Rahman MA, et al. S-nitrosylation at cysteine 498 of c-Src tyrosine kinase regulates nitric oxide-mediated cell invasion. J. Biol. Chem. 2010;285:3806-3814.

    Not in our library10.1074/jbc.m109.059782 (opens in a new tab)

  53. 53.

    Patwardhan P, Resh MD. Myristoylation and membrane binding regulate c-Src stability and kinase activity. Mol. Cell. Biol. 2010;30:4094-4107.

    Not in our library10.1128/mcb.00246-10 (opens in a new tab)

  54. 54.
  55. 55.

    Heppner DE, et al. Cysteine perthiosulfenic acid (Cys-SSOH): a novel intermediate in thiol-based redox signaling? Redox Biol. 2018;14:379-385.

    Not in our library10.1016/j.redox.2017.10.006 (opens in a new tab)

  56. 56.

    Bogdándi, V. et al. Speciation of reactive sulfur species and their reactions with alkylating agents: do we have any clue about what is present inside the cell? Br. J. Pharmacol.10.1111/bph.14394 (2018).

    Not in our library10.1111/bph.14394 (opens in a new tab)

  57. 57.

    Fabian MA, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 2005;23:329-336.

    Not in our library10.1038/nbt1068 (opens in a new tab)

  58. 58.

    Gushwa NN, Kang S, Chen J, Taunton J. Selective targeting of distinct active site nucleophiles by irreversible Src-family kinase inhibitors. J. Am. Chem. Soc. 2012;134:20214-20217.

    Not in our library10.1021/ja310659j (opens in a new tab)

  59. 59.

    Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer. 2009;9:28-39.

    Not in our library10.1038/nrc2559 (opens in a new tab)

  60. 60.

    Seeliger MA, et al. High yield bacterial expression of active c-Abl and c-Src tyrosine kinases. Protein Sci. 2005;14:3135-3139.

    Not in our library10.1110/ps.051750905 (opens in a new tab)

  61. 61.

    Best RB, et al. Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone ϕ, ψ and side-chain χ1 and χ2 dihedral angles. J. Chem. Theory Comput. 2012;8:3257-3273.

    Not in our library10.1021/ct300400x (opens in a new tab)

  62. 62.

    Becke AD. Density-functional thermochemistry. III. The role of exact exchange. J. Chem. Phys. 1993;98:5648-5652.

    Not in our library10.1063/1.464913 (opens in a new tab)

  63. 63.

    Bochevarov AD, et al. Jaguar: A high‐performance quantum chemistry software program with strengths in life and materials sciences. Int. J. Quantum Chem. 2013;113:2110-2142.

    Not in our library10.1002/qua.24481 (opens in a new tab)

  64. 64.

    Jo S, Kim T, Iyer VG, Im W. CHARMM-GUI: a web-based graphical user interface for CHARMM. J. Comput. Chem. 2008;29:1859-1865.

    Not in our library10.1002/jcc.20945 (opens in a new tab)

  65. 65.

    Liao, C. et al. Conformational heterogeneity of bax helix 9 dimer for apoptotic pore formation. Sci. Rep.6, 29502 (2016).

    Not in our library10.1038/srep29502 (opens in a new tab)

  66. 66.

    Phillips JC, et al. Scalable molecular dynamics with NAMD. J. Comput. Chem. 2005;26:1781-1802.

    Not in our library10.1002/jcc.20289 (opens in a new tab)

  67. 67.

    Shaw, D. E. et al. Millisecond-scale molecular dynamics simulations on Anton. In: Proc. of the Conference on High Performance Computing Networking, Storage and Analysis (ACM, 2009).

    Not in our library

Cited by papers we hold 4

Questions about this paper

We email you if it is retracted, withdrawn, corrected or flagged.

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.